
MacroGenics (MGNX) Stock Forecast & Price Target
MacroGenics (MGNX) Analyst Ratings
Bulls say
Macrogenics Inc has established a strong foundation for growth through its advanced antibody engineering capabilities and a diverse pipeline of product candidates aimed at critical therapeutic areas, particularly in oncology. The company is poised for increased momentum, with the anticipation of a greater flow of clinical trial data from its variety of earlier-stage programs, highlighting its commitment to innovation and strategic importance within the pharmaceutical landscape. Moreover, the initiation of patient dosing in pivotal clinical trials, such as the P2 LINNET trial for lorigerlimab, presents additional opportunities for partnership and capital generation, further enhancing the company’s financial outlook.
Bears say
Macrogenics Inc reported a disappointing financial performance, with a GAAP net loss of $41 million, significantly surpassing both company and consensus estimates of $(0.39) and $(0.73) per share, respectively. The company's lower-than-expected revenue of $13 million and a 23% year-over-year decrease in research and development spending indicate challenges in advancing its clinical pipeline of antibody-based therapeutics. Additionally, while operating expenses decreased by 19% year-over-year, the persistent and widening net losses highlight ongoing financial vulnerabilities that undermine confidence in the company's future profitability prospects.
This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.
MacroGenics (MGNX) Analyst Forecast & Price Prediction
Start investing in MacroGenics (MGNX)
Order type
Buy in
Order amount
Est. shares
0 shares